|1.||Razeghi, Effat: 1 article (05/2012)|
|2.||Ranjbarnovin, Neda: 1 article (05/2012)|
|3.||Khazaeipour, Zahra: 1 article (05/2012)|
|4.||Ramezani, Morteza: 1 article (05/2012)|
|5.||Ahmadi, Farokhlagha: 1 article (05/2012)|
|6.||Kuruma, K A M: 1 article (01/2007)|
|7.||de Carvalho, J F: 1 article (01/2007)|
|8.||Borba, E F: 1 article (01/2007)|
|9.||Lopes, M H: 1 article (01/2007)|
|10.||Bonfá, E: 1 article (01/2007)|
|1.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
|2.||Kidney Diseases (Kidney Disease)
03/01/2004 - "A total of 316 students non-reactive for any serological marker of hepatitis B virus infection were vaccinated: 77 (24.4%) with the Butang vaccine, 71 (22.5%) with Euvax-B, 85 (26.9%) with Hepavax-Gene and, for comparison, 83 (26.2%) with Engerix-B (GlaxoSmithKline), whose efficacy in young adults at the dose used here has been confirmed in previous studies. "
01/01/2004 - "Euvax-B was clinically identical (not inferior) to the EngerixB reference vaccine, and either vaccine could be used to achieve the World Health Organization goal of immunizing all infants against hepatitis B. "
12/01/2001 - "In 1998, Bulgaria adopted a recombinant DNA yeast-derived hepatitis B (HB) vaccine (Euvax B) for universal vaccination of all Bulgarian newborns on a 0-1-6 month schedule, the first dose to be given within 24 h of birth. "
01/01/2004 - "To compare two pediatric recombinant hepatitis B vaccines-the Engerix-B reference vaccine and the Euvax-B vaccine-in terms of immunogenicity and reactogenicity, and also to investigate their interchangeability, that is, whether a three-dose hepatitis B vaccination schedule begun with a first dose of Engerix-B could be completed with two doses of Euvax-B. "
|5.||Chronic Kidney Failure (Chronic Renal Failure)
05/01/2012 - "In an open, randomized clinical trial, we compared seroconversion rates in 51 predialysis patients with mild and moderate chronic renal failure who received either 4 doses of 40 μg or 3 doses of 20 μg of Euvax B recombinant hepatitis B vaccine administered at 0, 1, 2, 6 and 0, 1, 6 months, respectively. "
|1.||Recombinant DNA (Recombinant DNA Research)
|3.||Hepatitis B Surface Antigens (HBsAg)
|4.||Hepatitis B Vaccines (Hepatitis B Vaccine)